MONOCLONAL antibody injection nirsevimab is highly effective in real-world conditions at preventing severe respiratory syncytial virus (RSV) infections in infants, new research has found.
Looking at 27 studies covering five countries - France, Italy, Luxembourg, Spain and the United States - the meta-analysis found on average that nirsevimab reduces the risk of hospitalisation due to RSV infection by 83%, intensive care admissions by 81%, and instances of lower respiratory tract infections by 75% in babies aged 12 months and younger.
In Australia, as part of the National RSV Mother & Infant Protection Program, the antibody is offered free of charge to babies born to mothers who did not receive the RSV vaccine (PD 20 Jan).
The above article was sent to subscribers in Pharmacy Daily's issue from 05 May 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 May 25
